Published on : Mar 09, 2018
Albany, New York, March 9, 2018: The rising prevalence of exocrine pancreatic insufficiency around the world has created significant demand for effective treatment methods. It has been analyzed that EPI results due to a number of conditions such as cystic fibrosis, cytomegalovirus infection, pancreatic cancer, chronic pancreatitis, and HIV/AIDS. Owing to the alarming increase in the prevalence of cystic fibrosis, the risk of EPI also increases substantially. These facts have resulted for market growth of EPI therapeutics and diagnostic widely, finds a new study published to the online repository of Market Research Hub, and captioned as “Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2025”. According to the key evaluations, the global EPI therapeutics and diagnostics market was valued at US$3,397.5 mn in 2016 and is projected to reach US$6,414.4 mn by 2025, expanding at a remarkable CAGR of 7.2% from 2017 to 2025.
Geographically, the North America market accounts for a significant share in the overall market owing to the large patient pool and a rising prevalence of cystic fibrosis and diabetes. Another fact about the market highlighted in the study is that Asia Pacific will outpace other regional markets over the forecast period owing to the increasing population of geriatrics in countries such as China, Japan, and Singapore. Other prime regions emphasized in the study are Europe, Latin America and Middle East and Africa.
In the initial segment, the market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments of the market. The detailed overview of global EPI therapeutics and diagnostics market, evaluates market performance in terms of revenue, followed by analysis of key trends, drivers, and restraints witnessed in the past few years.
Furthermore, the study on exocrine pancreatic insufficiency market segments the global market on the basis of type including therapeutics and diagnostics. The diagnostics segment is further sub-segmented into blood tests, endoscopic ultra-sonography, magnetic resonance imaging [MRI], and CT scanning. Of these, CT scans are conventionally preferred and the most adopted method used for diagnosing EPI. Apart from that MRI segment is likely to outpace other segments in terms of CAGR during the forecast period, as it is more sensitive than CT scans.
At last, the report comprises a detailed company profiles section including a synopsis of the key players functioning in the global exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market. Major players profiled in this report embrace Allergan plc, Nordmark Arzneimittel GmbH & Co. KG, AzurRx Biopharma, Inc., Digestive Care, Inc., Anthera Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Cilian AG, Abbvie, Inc., and others.
Request a Sample with TOC in a PDF format : https://www.marketresearchhub.com/enquiry.php?type=S&repid=213302
About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
For Enquiries, Call :
+1-800-998-4852US Toll Free
Email : email@example.com